Active Biotech AB (ACTI.ST)
-Stockholm 51.00 
1.75(3.32%) 11:30AM EDT
| Prev Close: | 52.75 |
|---|
| Open: | 52.50 |
|---|
| Bid: | 50.75 |
|---|
| Ask: | 51.50 |
|---|
| 1y Target Est: | 41.29 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 50.75 - 52.50 |
|---|
| 52wk Range: | 37.00 - 69.50 |
|---|
| Volume: | 80,200 |
|---|
| Avg Vol (3m): | 115,545 |
|---|
| Market Cap: | N/A |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in SEK.
Headlines
- New data to be presented at the 2013 ASCO Annual Meeting show Active Biotech's commitment to oncology researchThomson Reuters ONE(Thu, May 16)
- Annual General Meeting of Active Biotech ABThomson Reuters ONE(Thu, May 16)
- Q1 2013 Active Biotech AB Earnings Release - Time Not SuppliedCCBN(Thu, Apr 25)
- Active Biotech AB Interim Report January - March 2013Thomson Reuters ONE(Thu, Apr 25)
- Active Biotech and Ipsen update the analysis plan for the 10TASQ10 trial evaluating tasquinimod in the treatment of prostate cancerThomson Reuters ONE(Thu, Apr 25)
- Annual Report 2012 Active Biotech AB (publ)Thomson Reuters ONE(Mon, Apr 15)
- Active Biotech - Notice of Annual General Meeting of ShareholdersThomson Reuters ONE(Thu, Apr 11)
- Number of shares and votes in Active BiotechThomson Reuters ONE(Thu, Mar 28)
- EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSISThomson Reuters ONE(Thu, Mar 21)
- Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression – Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple SclerosisBusiness Wire(Thu, Mar 21)
- FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSISThomson Reuters ONE(Wed, Mar 6)
- First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple SclerosisBusiness Wire(Wed, Mar 6)
- Active Biotech Rises as Investor AB Buys Stake: Stockholm Moverat Bloomberg(Wed, Mar 6)
- Active Biotech raises SEK 270 million through a directed new issue to InvestorThomson Reuters ONE(Wed, Mar 6)
- Active Biotech AB Year-end report January - December 2012Thomson Reuters ONE(Thu, Feb 14)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-11)
: | N/A |
|---|
| Quarterly EPS Est
(Dec-11)
: | N/A |
|---|
| Mean Recommendation*: | 2.7 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
No business summary available forACTI.ST.